Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy

• The study aims to test the hypothesis that SGCT is effective in preventing paclitaxel-induced peripheral neuropathy.
• The primary objective is to determine the incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy, assessed using the CTCAE version 5.0. Secondary objectives include evaluating the incidence of grade 2 or higher paclitaxel-induced motor peripheral neuropathy using CTCAE version 5.0, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX) score, the incidence of grade D or higher paclitaxel-induced sensory and motor peripheral neuropathy as measured by the Patient Neurotoxicity Questionnaire (PNQ), and the outcomes from the monofilament test.
• Sample size formula based on Bernard R. Fundamentals of biostatistics. 5th ed. Duxbery: Thomson learning; 2000. Enrollment of 36 patients.
• Randomization into two groups. The intervention arm will receive SGCT, while the control arm will receive non-compressive plastic gloves. The duration of treatment is 9 weeks.
• Enrollment and data monitoring are assessed by staff at the Oncology Unit, Rajavithi Hospital, and the data will be recorded in a computer-based information system.
• Data assessment will be conducted on weeks 0, 3, 6, and 9 during the chemotherapy treatment.
• Data analyzed by descriptive and inferential statistics.

Inclusion criteria

• Signed Informed Consent Form
• Age 18 years or older at the time of signing Informed Consent Form
• Patients with any pathological diagnosis of solid tumor, such as breast cancer or lung cancer
• Patients scheduled to be receiving intravenous paclitaxel or paclitaxel-based regimen every 3 weeks

Exclusion criteria

• Patients whose received chemotherapeutic agents that could cause neuropathy, e.g. taxane-based or platinum-based chemotherapy and anti-microtubule
• History of neuropathy
• History of carpal tunnel syndrome
• History of allergic reactions to latex or gloves
• Patients receiving treatments that may treat neuropathy, e.g. amitriptyline, gabapentin, Acetyl L-Carnitine and Ganglioside-monosialic acid, acupuncture, cryotherapy or exercise therapy
• History of Raynaud phenomenon
• History of wounds or large scars on hands
• Pregnancy or breastfeeding
• History of poorly controlled diabetes; HbA1c>6.5